Core Viewpoint - Ekso Bionics (EKSO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is effective for individual investors as it focuses on earnings estimate revisions, which are strongly correlated with near-term stock price movements [2][3]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade for Ekso Bionics reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [4]. - Over the past three months, the Zacks Consensus Estimate for Ekso Bionics has increased by 77%, indicating a positive trend in earnings estimates [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - Ekso Bionics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Company Performance - Ekso Bionics reported a quarterly loss of $1.24 per share, slightly worse than the Zacks Consensus Estimate of a loss of $1.20, and an improvement from a loss of $1.95 per share a year ago [1] - The company posted revenues of $2.06 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 55.57%, and down from $4.95 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS or revenue estimates [2] Stock Performance - Ekso Bionics shares have declined approximately 47.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Ekso Bionics is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$1.35 on revenues of $4.29 million, and for the current fiscal year, it is -$5.10 on revenues of $18.22 million [7] - The outlook for the Medical - Instruments industry, where Ekso Bionics operates, is currently in the bottom 32% of over 250 Zacks industries, which may impact the stock's performance [8]